Eli Lilly Continues To Climb As Alzheimer's Drug Gains FDA Approval

StockCharts.com Last week I wrote an update on the largest overall holding at my firm, Eli Lilly and Company (NYSE:LLY), in an article titled, "Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs?" Following strong earnings, approval of its blockbuster diabetes drug Mounjaro for weight loss, and a growing demand for weight loss drug solutions, I raised my 5-year target price to $1,455. This update was based on a very conservative projected growth rate of 19% per year and a multiple that I feel Li ...